PMID- 2692843
OWN - NLM
STAT- MEDLINE
DCOM- 19900302
LR  - 20220330
IS  - 0743-4863 (Print)
IS  - 0743-4863 (Linking)
VI  - 6
IP  - 3
DP  - 1989
TI  - Tumoritropic and lymphotropic principles of macromolecular drugs.
PG  - 193-210
AB  - The advantages and disadvantages of macromolecular drugs, particularly on 
      synthetic polymer-protein conjugates, are described in this article. Improvements 
      in protein drugs, after tailoring with polymers, are as follows: increased plasma 
      half-life, loss of antigenecity, lymphotropism, and, especially, preferred 
      tumor-targeting efficiency and long-term retention in the tumor tissues. 
      Hydrophobic character can make a drug also possible for oily formulation. 
      Explained are the rationales of macromolecular drugs to preferential delivery to 
      the tumor and lymphatic tissues based on our finding on pathological/anatomical 
      differences of the blood and lymphatic vasculatures. Enhanced vascular 
      permeability, which facilitates the macromolecular drug-leakage out of the blood 
      vessel, is discussed. A model compound, which is discussed in detail, is 
      smancs--styrene-co-maleic acid conjugated neocarzinostatin (MW 16 K). Some data 
      on polymer-conjugated enzymes as potential therapeutic agents are described as 
      well.
FAU - Maeda, H
AU  - Maeda H
AD  - Department of Microbiology, Kumamoto University Medical School, Japan.
FAU - Matsumura, Y
AU  - Matsumura Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Crit Rev Ther Drug Carrier Syst
JT  - Critical reviews in therapeutic drug carrier systems
JID - 8511159
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage
MH  - Humans
MH  - Lymphatic System/*drug effects
MH  - Neoplasms/blood supply/*drug therapy
MH  - Regional Blood Flow/drug effects
RF  - 55
EDAT- 1989/01/01 00:00
MHDA- 1989/01/01 00:01
CRDT- 1989/01/01 00:00
PHST- 1989/01/01 00:00 [pubmed]
PHST- 1989/01/01 00:01 [medline]
PHST- 1989/01/01 00:00 [entrez]
PST - ppublish
SO  - Crit Rev Ther Drug Carrier Syst. 1989;6(3):193-210.